Arima Hiroshi, Fujimoto Masakazu, Nishikori Momoko, Kitano Toshiyuki, Kishimoto Wataru, Hishizawa Masakatsu, Kondo Tadakazu, Yamashita Kouhei, Hirata Masahiro, Haga Hironori, Takaori-Kondo Akifumi
a Department of Hematology and Oncology , Graduate School of Medicine, Kyoto University , Kyoto , Japan.
b Department of Diagnostic Pathology, Graduate School of Medicine , Kyoto University , Kyoto , Japan.
Leuk Lymphoma. 2018 Sep;59(9):2085-2095. doi: 10.1080/10428194.2017.1410884. Epub 2017 Dec 18.
Activation-induced cytidine deaminase (AID) plays important roles in the development of diffuse large B-cell lymphoma (DLBCL); however, its prognostic value remains controversial. Here, we evaluated AID expression in 71 DLBCL patients treated with R-CHOP by immunohistochemistry and investigated its prognostic significance. AID expression was detected in 40.8% of DLBCL samples and associated with IRF4 expression. Notably, AID expression correlated with shorter progression-free survival and overall survival for patients with high (3-5) international prognostic index (IPI) score. Moreover, it was a strong predictor of poor overall response to salvage therapy after relapse or disease progression, which may suggest its role in promoting the evolution of tumors into highly refractory disease at relapse. Our findings indicate that AID expression effectively discriminates between IPI-high score patients with different survival outcomes, and suggest that initial disease control would be particularly important for the treatment of IPI-high score patients with AID-positive DLBCL.
活化诱导胞苷脱氨酶（AID）在弥漫性大B细胞淋巴瘤（DLBCL）的发生发展中起重要作用；然而，其预后价值仍存在争议。在此，我们通过免疫组织化学评估了71例接受R-CHOP治疗的DLBCL患者中AID的表达情况，并研究了其预后意义。在40.8%的DLBCL样本中检测到AID表达，且与IRF4表达相关。值得注意的是，对于国际预后指数（IPI）评分高（3 - 5分）的患者，AID表达与较短的无进展生存期和总生存期相关。此外，它是复发或疾病进展后挽救治疗总体反应不佳的有力预测指标，这可能表明其在促进肿瘤在复发时演变为高度难治性疾病中的作用。我们的研究结果表明，AID表达能有效区分具有不同生存结果的高IPI评分患者，并提示对于AID阳性的高IPI评分DLBCL患者，初始疾病控制对治疗尤为重要。
